Institution Directory

Clinical trials at Washington University School of Medicine

Sites in St. Louis, MO

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1748

Shown on this page

Current sort

Stored official records

Conditions: Advanced Breast Cancer, Advanced Ovarian Cancer, Advanced Solid Tumor
Interventions: BMS-986500, Fulvestrant, Palbociclib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 15
States / cities: Birmingham, Alabama • Fullerton, California • Greenbrae, California + 11 more

Conditions: Bladder Carcinoma, Breast Carcinoma, Colorectal Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Liver Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm, Ovarian Carcinoma, Pancreatic Carcinoma, Prostate Carcinoma
Interventions: Biospecimen Collection, Device Usage, Electronic Health Record Review, Multi-Cancer Detection Test, Questionnaire Administration; Procedure · Device · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 45 Years to 75 Years
Enrollment: 24,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 45
States / cities: Pleasanton, California • Cheyenne Wells, Colorado • Denver, Colorado + 37 more

Conditions: Autosomal Dominant Polycystic Kidney Disease
Interventions: ABBV-CLS-628, Placebo; Drug
Lead sponsor: Calico Life Sciences LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 40
States / cities: Birmingham, Alabama • Huntington Park, California • Los Angeles, California + 34 more

Conditions: Heart Failure
Interventions: Alleviant ALV1 System, Sham-Control; Device · Other
Lead sponsor: Alleviant Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 40
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 31 more

Conditions: Advanced Melanoma
Interventions: EIK1001, Pembrolizumab (KEYTRUDA® ); Drug
Lead sponsor: Eikon Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2040
U.S. locations: 14
States / cities: Chandler, Arizona • Hot Springs, Arkansas • Los Angeles, California + 11 more

Conditions: Labor Stage, First, Prolonged Labor
Interventions: Circuit of maternal position changes during labor; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 12 Years and older · Female only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
Interventions: Acasunlimab, Docetaxel, Pembrolizumab; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 36
States / cities: Tucson, Arizona • Los Angeles, California • Vallejo, California + 28 more

Conditions: Non-small Cell Lung Cancer Stage III
Interventions: Cemiplimab-Rwlc; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • St Louis, Missouri • Charlottesville, Virginia

Conditions: Multiple Myeloma
Interventions: Arlocabtagene Autoleucel; Biological
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 41
States / cities: Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 33 more

Conditions: Prostate Cancer Metastatic
Interventions: Abiraterone acetate, Dexamethasone, Enzalutamide, Fludrocortisone acetate, Hydrocortisone, Opevesostat, Prednisone; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 48
States / cities: Orange, California • Palo Alto, California • Riverside, California + 41 more

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Letermovir; Procedure · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 2 Years to 18 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 33
States / cities: Birmingham, Alabama • Oakland, California • San Francisco, California + 28 more

Conditions: Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
Interventions: (8gy x 3), Nivolumab, Platinum Doublet; Radiation · Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 4
States / cities: St Louis, Missouri • The Bronx, New York • White Plains, New York + 1 more

About this Washington University School of Medicine institution page

What this page lists: ClinicalTrials.gov records that list Washington University School of Medicine in St. Louis, MO as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Washington University School of Medicine

Filter and sort this campus

Stored official records

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

The Vanguard Study: Testing a New Way to Screen for Cancer

ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Alleviant ALLAY-HFrEF Study

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

Maternal Maneuvers During Prolonged Labor

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

About this Washington University School of Medicine institution page